<MedlineCitation Status="Completed">
<MedlineID>10011159</MedlineID>
<PMID>420711</PMID>
<DateCreated>
<Year>1979</Year>
<Month>04</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>1979</Year>
<Month>04</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0004-3591</ISSN>
<JournalIssue>
<Volume>22</Volume>
<Issue>2</Issue>
<PubDate>
<Year>1979</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Fatty lesions of both humeri in a patient on corticosteroids and cyclophosphamide.</ArticleTitle>
<Pagination>
<MedlinePgn>199-200</MedlinePgn>
</Pagination>
<AuthorList>
<Author>
<LastName>Wilkenfeld</LastName>
<ForeName>M J</ForeName>
<Initials>MJ</Initials>
</Author>
<Author>
<LastName>Sliwinski</LastName>
<ForeName>A J</ForeName>
<Initials>AJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Arthritis Rheum</MedlineTA>
<NlmUniqueID>0370605</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>50-18-0</RegistryNumber>
<NameOfSubstance>Cyclophosphamide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>53-03-2</RegistryNumber>
<NameOfSubstance>Prednisone</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName>Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Arthritis, Rheumatoid</DescriptorName>
<QualifierName>drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Biopsy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Bone Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y">chemically induced</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Bone Marrow Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y">chemically induced</QualifierName>
<QualifierName>pathology</QualifierName>
<QualifierName>radiography</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Case Report</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Cyclophosphamide</DescriptorName>
<QualifierName>administration &#38; dosage</QualifierName>
<QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName>therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Human</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Humerus</DescriptorName>
<QualifierName>drug effects</QualifierName>
<QualifierName>pathology</QualifierName>
<QualifierName>radiography</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Osteolysis, Essential</DescriptorName>
<QualifierName MajorTopicYN="Y">chemically induced</QualifierName>
<QualifierName>pathology</QualifierName>
<QualifierName>radiography</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Prednisone</DescriptorName>
<QualifierName>administration &#38; dosage</QualifierName>
<QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName>therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
